QLT and VasoGenix to Develop Heart Failure Treatment

Private biopharmaceutical firm, VasoGenix Pharmaceuticals, has signed a worldwide agreement with QLT USA Inc. to develop a potentially major new treatment for congestive heart failure. The agreement covers the development of a sustained-release formulation of VasoGenix's calcitonin gene related peptide (CGRP) using QLT's Atrigel biodegradable sustained release drug delivery system.

Yahoo News (http://uk.biz.yahoo.com/050411/241/fg3ne.html)